High-Throughput Screening to Identify Novel Compounds Affecting the Genome Editing Efficiency of CRISPR System DOI Creative Commons
Jiasong Chang, Xiulong Yang, Tong Zhang

и другие.

Molecules, Год журнала: 2025, Номер 30(8), С. 1811 - 1811

Опубликована: Апрель 17, 2025

Genome editing is a promising therapeutic strategy for genetic disorders by modifying the genome precisely, especially CRISPR/Cas9 system. However, major limitation of in gene therapy biosafety issues caused off-target effects. Compounds that can modulate efficiency system, those reducing effects, are potentially useful pharmacological tools improving effectiveness and safety editing. Here, we performed high-throughput screening HEK 293FT cells to discover compounds decrease or increase system from 9930 compounds. After two rounds screening, identified CP-724714, ErbB2 (HER2) tyrosine kinase inhibitor, decreased reduced effects suppressing CRISPR/Cas9, was thus named CRISPR decelerator (or inhibitor), while Clofarabine, DNA synthesis increased accelerator. We further four (Tranilast, Cerulenin, Rosolic acid Resveratrol) affected single-strand annealing (SSA) repair. Among them, Tranilast, Cerulenin potential SSA decelerators, Resveratrol These may be optimizing mammalian manipulation techniques.

Язык: Английский

Transforming cancer treatment: integrating patient-derived organoids and CRISPR screening for precision medicine DOI Creative Commons

Ziyi Zhu,

John Paul Shen,

Paul Chi-Lui Ho

и другие.

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Март 25, 2025

The persistently high mortality rates associated with cancer underscore the imperative need for innovative, efficacious, and safer therapeutic agents, as well a more nuanced understanding of tumor biology. Patient-derived organoids (PDOs) have emerged innovative preclinical models significant translational potential, capable accurately recapitulating structural, functional, heterogeneous characteristics primary tumors. When integrated cutting-edge genomic tools such CRISPR, PDOs provide powerful platform identifying driver genes novel targets. This comprehensive review delves into recent advancements in CRISPR-mediated functional screens leveraging across diverse types, highlighting their pivotal role high-throughput genomics microenvironment (TME) modeling. Furthermore, this highlights synergistic potential integrating CRISPR immunotherapy, focusing on uncovering immune evasion mechanisms improving efficacy immunotherapeutic approaches. Together, these technologies offer promise advancing precision oncology.

Язык: Английский

Процитировано

0
High-Throughput Screening to Identify Novel Compounds Affecting the Genome Editing Efficiency of CRISPR System DOI Creative Commons
Jiasong Chang, Xiulong Yang, Tong Zhang

и другие.

Molecules, Год журнала: 2025, Номер 30(8), С. 1811 - 1811

Опубликована: Апрель 17, 2025

Genome editing is a promising therapeutic strategy for genetic disorders by modifying the genome precisely, especially CRISPR/Cas9 system. However, major limitation of in gene therapy biosafety issues caused off-target effects. Compounds that can modulate efficiency system, those reducing effects, are potentially useful pharmacological tools improving effectiveness and safety editing. Here, we performed high-throughput screening HEK 293FT cells to discover compounds decrease or increase system from 9930 compounds. After two rounds screening, identified CP-724714, ErbB2 (HER2) tyrosine kinase inhibitor, decreased reduced effects suppressing CRISPR/Cas9, was thus named CRISPR decelerator (or inhibitor), while Clofarabine, DNA synthesis increased accelerator. We further four (Tranilast, Cerulenin, Rosolic acid Resveratrol) affected single-strand annealing (SSA) repair. Among them, Tranilast, Cerulenin potential SSA decelerators, Resveratrol These may be optimizing mammalian manipulation techniques.

Язык: Английский

Процитировано

0